Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 SCHELLING CERTIFICATION PURSUANT TO SEC 906 - Acer Therapeutics Inc. | acer-ex321_164.htm |
| EX-31.2 - EX-31.2 PALMIN CERTIFICATION PURSUANT TO SEC 302 - Acer Therapeutics Inc. | acer-ex312_165.htm |
| EX-31.1 - EX-31.1 SCHELLING CERTIFICATION PURSUANT TO SEC 302 - Acer Therapeutics Inc. | acer-ex311_166.htm |
| EX-23.1 - EX-23.1 AUDITORS CONSENT - Acer Therapeutics Inc. | acer-ex231_162.htm |
| EX-21.1 - EX-21.1 LIST OF SUBSIDIARIES - Acer Therapeutics Inc. | acer-ex211_161.htm |
| EX-10.19 - EX-10.19 SUBLEASE AND CONSENT - Acer Therapeutics Inc. | acer-ex1019_281.htm |
| 10-K - 10-K - Acer Therapeutics Inc. | acer-10k_20171231.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Acer Therapeutics Inc. (the “Company”) on Form 10-K for the period ending December 31, 2017 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Harry Palmin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
|
1. |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: March 7, 2018 |
|
By: |
/s/ Harry Palmin |
|
|
|
|
Harry Palmin Chief Financial Officer (Principal Financial and Accounting Officer) |